1,368
Views
7
CrossRef citations to date
0
Altmetric
Extra Views

Potential approaches for heterologous prion protein treatment of prion diseases

, &
Pages 18-24 | Received 21 Oct 2015, Accepted 17 Nov 2015, Published online: 04 Apr 2016

REFERENCES

  • Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science 2001; 294:1726-8; PMID:11721058; http://dx.doi.org/10.1126/science.1066838
  • Hetz C, Maundrell K, Soto C. Is loss of function of the prion protein the cause of prion disorders? Trends Mol Med 2003; 9:237-43; PMID:12829011; http://dx.doi.org/10.1016/S1471-4914(03)00069-8
  • Caughey B, Chesebro B. Transmissible spongiform encephalopathies and prion protein interconversions. Adv Virus Res 2001; 56:277-311; PMID:11450303; http://dx.doi.org/10.1016/S0065-3527(01)56031-5
  • Prusiner SB, Scott M, Foster D, Pan KM, Groth D, Mirenda C, Torchia M, Yang SL, Serban D, Carlson GA, et al. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 1990; 63:673-86; PMID:1977523; http://dx.doi.org/10.1016/0092-8674(90)90134-Z
  • Mallik S, Yang W, Norstrom EM, Mastrianni JA. Live cell fluorescence resonance energy transfer predicts an altered molecular association of heterologous PrPSc with PrPC. J Biol Chem 285:8967-75; PMID:20086009; http://dx.doi.org/10.1074/jbc.M109.058107
  • Bett C, Fernandez-Borges N, Kurt TD, Lucero M, Nilsson KP, Castilla J, Sigurdson CJ. Structure of the beta2-alpha2 loop and interspecies prion transmission. FASEB J 26:2868-76; PMID:22490928; http://dx.doi.org/10.1096/fj.11-200923
  • Giachin G, Biljan I, Ilc G, Plavec J, Legname G. Probing early misfolding events in prion protein mutants by NMR spectroscopy. Molecules 18:9451-76; PMID:23966072; http://dx.doi.org/10.3390/molecules18089451
  • Singh J, Udgaonkar JB. Structural effects of multiple pathogenic mutations suggest a model for the initiation of misfolding of the prion protein. Angew Chem Int Ed Engl 54:7529-33; PMID:25959220; http://dx.doi.org/10.1002/anie.201501011
  • Liemann S, Glockshuber R. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein. Biochemistry 1999 38:3258-67; PMID:10079068; http://dx.doi.org/10.1021/bi982714g
  • Apetri AC, Surewicz K, Surewicz WK. The effect of disease-associated mutations on the folding pathway of human prion protein. J Biol Chem 2004; 279:18008-14; PMID:14761942; http://dx.doi.org/10.1074/jbc.M313581200
  • Singh J, Udgaonkar JB. Molecular Mechanism of the Misfolding and Oligomerization of the Prion Protein: Current Understanding and Its Implications. Biochemistry 54:4431-42; PMID:26171558; http://dx.doi.org/10.1021/acs.biochem.5b00605
  • Heppner FL, Musahl C, Arrighi I, Klein MA, Rulicke T, Oesch B, Zinkernagel RM, Kalinke U, Aguzzi A. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 2001; 294:178-82; PMID:11546838; http://dx.doi.org/10.1126/science.1063093
  • White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, Anstee D, Collinge J, Hawke S. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003; 422:80-3; PMID:12621436; http://dx.doi.org/10.1038/nature01457
  • Horiuchi M, Priola SA, Chabry J, Caughey B. Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci U S A 2000; 97:5836-41; PMID: 10811921; http://dx.doi.org/10.1073/pnas.110523897
  • Priola SA, Caughey B, Race RE, Chesebro B. Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol 1994; 68:4873-8; PMID:7913509
  • Vorberg I, Groschup MH, Pfaff E, Priola SA. Multiple amino acid residues within the rabbit prion protein inhibit formation of its abnormal isoform. J Virol 2003; 77:2003-9; PMID:12525634; http://dx.doi.org/10.1128/JVI.77.3.2003-2009.2003
  • Skinner PJ, Kim HO, Bryant D, Kinzel NJ, Reilly C, Priola SA, Ward AE, Goodman PA, Olson K, Seelig DM. Treatment of Prion Disease with Heterologous Prion Proteins. PLoS One 10:e013; 1993.
  • Gibbs CJ, Jr., Gajdusek DC. Experimental subacute spongiform virus encephalopathies in primates and other laboratory animals. Science 1973; 182:67-8; PMID:4199733; http://dx.doi.org/10.1126/science.182.4107.67
  • Barlow RM, Rennie JC. The fate of ME7 scrapie infection in rats, guinea-pigs and rabbits. Res Vet Sci 1976; 21:110-1; PMID:821118
  • Chianini F, Fernandez-Borges N, Vidal E, Gibbard L, Pintado B, de Castro J, Priola SA, Hamilton S, Eaton SL, Finlayson J, et al. Rabbits are not resistant to prion infection. Proc Natl Acad Sci U S A 109:5080-5; PMID:22416127; http://dx.doi.org/10.1073/pnas.1120076109
  • Vidal E, Fernandez-Borges N, Pintado B, Ordonez M, Marquez M, Fondevila D, Torres JM, Pumarola M, Castilla J. Bovine spongiform encephalopathy induces misfolding of alleged prion-resistant species cellular prion protein without altering its pathobiological features. J Neurosci 33:7778-86; PMID:23637170; http://dx.doi.org/10.1523/JNEUROSCI.0244-13.2013
  • Huang XQ, Hardison RC, Miller W. A space-efficient algorithm for local similarities. Comput Appl Biosci 1990; 6:373-81; PMID:2257499
  • Begley DJ. Transport of prion proteins across the blood-brain barrier. Exp Neurol 2009; 220:217-8; PMID:19682986; http://dx.doi.org/10.1016/j.expneurol.2009.08.006
  • Chabry J, Caughey B, Chesebro B. Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem 1998; 273:13203-7; PMID:9582363; http://dx.doi.org/10.1074/jbc.273.21.13203
  • Chabry J, Priola SA, Wehrly K, Nishio J, Hope J, Chesebro B. Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J Virol 1999; 73:6245-50; PMID:10400714
  • Mallucci GR, Ratte S, Asante EA, Linehan J, Gowland I, Jefferys JG, Collinge J. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J 2002; 21:202-10; PMID:11823413; http://dx.doi.org/10.1093/emboj/21.3.202
  • White MD, Farmer M, Mirabile I, Brandner S, Collinge J, Mallucci GR. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci U S A 2008; 105:10238-43; PMID:18632556; http://dx.doi.org/10.1073/pnas.0802759105
  • Toupet K, Compan V, Crozet C, Mourton-Gilles C, Mestre-Frances N, Ibos F, Corbeau P, Verdier JM, Perrier V. Effective gene therapy in a mouse model of prion diseases. PLoS One 2008; 3:e2773; http://dx.doi.org/10.1371/journal.pone.0002773